JP2005524402A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005524402A5 JP2005524402A5 JP2004501635A JP2004501635A JP2005524402A5 JP 2005524402 A5 JP2005524402 A5 JP 2005524402A5 JP 2004501635 A JP2004501635 A JP 2004501635A JP 2004501635 A JP2004501635 A JP 2004501635A JP 2005524402 A5 JP2005524402 A5 JP 2005524402A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disorder
- treating
- compound
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 8
- 230000004770 neurodegeneration Effects 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 210000002569 neuron Anatomy 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 206010012289 Dementia Diseases 0.000 claims 3
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 claims 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 206010061216 Infarction Diseases 0.000 claims 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims 2
- 208000016620 Tourette disease Diseases 0.000 claims 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000007574 infarction Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000000626 neurodegenerative effect Effects 0.000 claims 2
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 208000016686 tic disease Diseases 0.000 claims 2
- 206010065040 AIDS dementia complex Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 208000013016 Hypoglycemia Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 101710138657 Neurotoxin Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 238000011292 agonist therapy Methods 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000028329 epileptic seizure Diseases 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 239000002581 neurotoxin Substances 0.000 claims 1
- 231100000618 neurotoxin Toxicity 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/139,183 US20030018047A1 (en) | 2001-04-20 | 2002-05-03 | Therapeutic use of selective PDE10 inhibitors |
| US10/177,018 US20030032579A1 (en) | 2001-04-20 | 2002-06-20 | Therapeutic use of selective PDE10 inhibitors |
| PCT/IB2003/001684 WO2003093499A2 (en) | 2002-05-03 | 2003-04-22 | Therapeutic use of selective pde10 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005524402A JP2005524402A (ja) | 2005-08-18 |
| JP2005524402A5 true JP2005524402A5 (enExample) | 2006-06-15 |
Family
ID=29406263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004501635A Pending JP2005524402A (ja) | 2002-05-03 | 2003-04-22 | 療法における選択的ｐｄｅ１０阻害薬の使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20030032579A1 (enExample) |
| EP (1) | EP1504118A2 (enExample) |
| JP (1) | JP2005524402A (enExample) |
| KR (1) | KR20040106455A (enExample) |
| CN (1) | CN1668761A (enExample) |
| AU (1) | AU2003222395A1 (enExample) |
| BR (1) | BR0309746A (enExample) |
| CA (1) | CA2484600A1 (enExample) |
| HR (1) | HRP20041029A2 (enExample) |
| IL (1) | IL164778A0 (enExample) |
| MX (1) | MXPA04010777A (enExample) |
| NO (1) | NO20044470L (enExample) |
| PL (1) | PL373943A1 (enExample) |
| RU (1) | RU2303259C2 (enExample) |
| TW (1) | TWI269812B (enExample) |
| WO (1) | WO2003093499A2 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004253690B2 (en) * | 2003-06-30 | 2010-03-25 | Nycomed Gmbh | Pyrrolodihydroisoquinolines as PDE10 inhibitors |
| EP1641457B1 (en) * | 2003-06-30 | 2009-08-05 | Nycomed GmbH | Pyrrolo-dihydroisoquinoline derivatives as pde10 inhibitors |
| CA2556413A1 (en) * | 2004-02-18 | 2005-09-09 | Pfizer Products Inc. | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline |
| CA2568929A1 (en) * | 2004-06-07 | 2005-12-22 | Pfizer Products Inc. | Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| US20060019975A1 (en) * | 2004-07-23 | 2006-01-26 | Pfizer Inc | Novel piperidyl derivatives of quinazoline and isoquinoline |
| US7576080B2 (en) | 2004-12-23 | 2009-08-18 | Memory Pharmaceuticals Corporation | Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors |
| BRPI0518508A2 (pt) * | 2005-01-07 | 2008-11-25 | Pfizer Prod Inc | compostos de quinolina heteroaromÁticos e seu uso como inibidores de pde10 |
| DE602006006544D1 (de) * | 2005-01-12 | 2009-06-10 | Nycomed Gmbh | Neue pyrrolodihydroisochinoline als pde10-inhibitoren |
| WO2007129183A2 (en) | 2006-05-02 | 2007-11-15 | Pfizer Products Inc. | Bicyclic heteroaryl compounds as pde10 inhibitors |
| TW200817400A (en) * | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| TW200815436A (en) * | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| US20080090834A1 (en) * | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| JPWO2008026687A1 (ja) * | 2006-09-01 | 2010-01-21 | 杏林製薬株式会社 | ピラゾロピリジンカルボキサミド誘導体及びそれらを含有するホスホジエステラーゼ（ｐｄｅ）阻害剤 |
| US20090318385A1 (en) * | 2006-09-06 | 2009-12-24 | Yasushi Kohno | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient |
| US7786139B2 (en) | 2006-11-21 | 2010-08-31 | Omeros Corporation | PDE10 inhibitors and related compositions and methods |
| US8637528B2 (en) | 2007-03-27 | 2014-01-28 | Omeros Corporation | Use of PDE7 inhibitors for the treatment of movement disorders |
| MX2009010450A (es) * | 2007-03-27 | 2009-11-23 | Omeros Corp | El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento. |
| US7858620B2 (en) | 2007-09-19 | 2010-12-28 | H. Lundbeck A/S | Cyanoisoquinoline |
| WO2009070583A1 (en) * | 2007-11-30 | 2009-06-04 | Wyeth | Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10 |
| CA2706866A1 (en) * | 2007-11-30 | 2009-06-04 | Biotie Therapies Gmbh | Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 |
| WO2009068320A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| UA102693C2 (ru) | 2008-06-20 | 2013-08-12 | Х. Луннбек А/С | Производные фенилимидазола как ингибиторы фермента pde10a |
| WO2009158393A1 (en) | 2008-06-25 | 2009-12-30 | Envivo Pharmaceuticals, Inc. | 1, 2 disubstituted heterocyclic compounds |
| WO2010006130A2 (en) | 2008-07-09 | 2010-01-14 | Envivo Pharmaceuticals, Inc. | Pde-10 inhibitors |
| WO2010017236A1 (en) | 2008-08-05 | 2010-02-11 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| TW201018682A (en) * | 2008-09-25 | 2010-05-16 | Kyorin Seiyaku Kk | Heterocyclic biaryl derivative, and pde inhibitor comprising same as active ingredient |
| US20110224250A1 (en) * | 2008-10-09 | 2011-09-15 | Yasushi Kohno | Isoquinoline derivative, and pde inhibitor comprising same as active ingredient |
| WO2010128995A1 (en) | 2009-05-07 | 2010-11-11 | Envivo Pharmaceuticals, Inc. | Phenoxymethyl heterocyclic compounds |
| US9468637B2 (en) * | 2009-05-13 | 2016-10-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| TW201111383A (en) | 2009-05-29 | 2011-04-01 | Wyeth Llc | Substituted imidazo[1,5-a]quinoxalines as inhibitors of phosphodiesterase 10 |
| TW201102387A (en) * | 2009-06-08 | 2011-01-16 | Medicinova Inc | Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity |
| TWI485151B (zh) | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| TWI487705B (zh) | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物 |
| TW201200516A (en) | 2009-12-17 | 2012-01-01 | Lundbeck & Co As H | Phenylimidazole derivatives comprising an ethynylene linker as PDE10A enzyme inhibitors |
| KR101713453B1 (ko) | 2010-03-12 | 2017-03-07 | 오메로스 코포레이션 | Pde10 억제제 및 관련 조성물 및 방법 |
| TW201215607A (en) | 2010-07-02 | 2012-04-16 | Lundbeck & Co As H | Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor |
| TW201206935A (en) | 2010-07-16 | 2012-02-16 | Lundbeck & Co As H | Triazolo-and pyrazoloquinazoline derivatives as PDE10A enzyme inhibitor |
| JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
| CA2827724A1 (en) | 2011-02-18 | 2012-08-23 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US8592423B2 (en) | 2011-06-21 | 2013-11-26 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
| US8975276B2 (en) | 2011-06-29 | 2015-03-10 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| WO2013045607A1 (en) | 2011-09-30 | 2013-04-04 | H. Lundbeck A/S | Quinazoline linked heteroaromatic tricycle derivatives as pde10a enzyme inhibitors |
| WO2013050527A1 (en) | 2011-10-05 | 2013-04-11 | H. Lundbeck A/S | Quinazoline derivatives as pde10a enzyme inhibitors |
| KR20140090665A (ko) | 2011-11-09 | 2014-07-17 | 아비에 도이치란트 게엠베하 운트 콤파니 카게 | 포스포디에스테라제 타입 １０ａ의 억제제로서 유용한 헤테로사이클릭 카복스아미드 |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| TWI570124B (zh) | 2011-12-21 | 2017-02-11 | Ｈ 朗德貝克公司 | 作為ｐｄｅ１０ａ酵素抑制劑的喹啉衍生物 |
| US9138494B2 (en) | 2011-12-23 | 2015-09-22 | Abbvie Inc. | Radiolabeled PDE10A ligands |
| WO2013127817A1 (en) | 2012-02-27 | 2013-09-06 | H. Lundbeck A/S | Imidazole derivatives as pde10a enzyme inhibitors |
| HK1206250A1 (en) * | 2012-06-26 | 2016-01-08 | Janssen Pharmaceutica Nv | Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and ped 10 inhibitors for use in the treatment of neurological or metabolic disorders |
| UY34980A (es) | 2012-08-17 | 2014-03-31 | Abbvie Inc | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a |
| KR20150056844A (ko) | 2012-09-17 | 2015-05-27 | 아비에 도이치란트 게엠베하 운트 콤파니 카게 | 포스포디에스테라제 타입 10a의 신규 억제제 화합물 |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| US9790203B2 (en) | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| MX2015010971A (es) | 2013-02-27 | 2015-10-26 | Mochida Pharm Co Ltd | Derivado novedoso de pirazol. |
| US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| AU2014230745A1 (en) | 2013-03-14 | 2015-09-03 | AbbVie Deutschland GmbH & Co. KG | Novel inhibitor compounds of phosphodiesterase type 10A |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| NZ630810A (en) | 2014-04-28 | 2016-03-31 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| NZ716462A (en) | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| CA2980801A1 (en) | 2015-04-24 | 2016-10-27 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| CA3003611C (en) | 2015-11-04 | 2022-11-01 | Omeros Corporation | Solid state forms of a pde10 inhibitor |
| JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| CN112996492A (zh) * | 2018-09-05 | 2021-06-18 | 阿姆斯特丹大学 | Pde11或pde2抑制剂用于治疗帕金森氏疾病的用途 |
| CN110346004B (zh) * | 2019-08-16 | 2020-08-21 | 杭州山科智能科技股份有限公司 | 一种双声道超声时差法的流量测量数据融合方法 |
| BR112022024751A2 (pt) * | 2020-06-05 | 2023-03-07 | Noema Pharma Ag | Uso de um inibidor de fosfodiesterase 10 para o tratamento da síndrome de tourette |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ194348A (en) * | 1979-07-26 | 1982-09-14 | Merrell Toraude & Co | Fluorinated methyl-beta-alanine derivatives and pharmaceutical compositions |
| DE3224100A1 (de) * | 1982-06-29 | 1983-12-29 | Michael 6950 Schriesheim Long | Depotmedikament zur behandlung von psychologischen aberrationen, erkrankungen und dergleichen |
| PH31213A (en) * | 1993-05-25 | 1998-05-05 | Daiichi Seiyaku Co | Drug for neuroprotection. |
| US5487976A (en) * | 1993-10-15 | 1996-01-30 | Cornell Research Foundation, Inc. | DNA encoding an insect gamma-aminobutyric acid (GABA) receptor subunit cells expressing it, and pesticide screening methods using such cells |
| US20040152106A1 (en) * | 1999-10-07 | 2004-08-05 | Robertson Harold A. | Gene necessary for striatal function, uses thereof, and compounds for modulating same |
| ES2256415T3 (es) * | 2001-07-31 | 2006-07-16 | Pfizer Products Inc. | Ensayos basados en celulas y secuencias para la fosfodiesterasa 10a. |
-
2002
- 2002-06-20 US US10/177,018 patent/US20030032579A1/en not_active Abandoned
-
2003
- 2003-04-22 PL PL03373943A patent/PL373943A1/xx not_active Application Discontinuation
- 2003-04-22 EP EP03717481A patent/EP1504118A2/en not_active Withdrawn
- 2003-04-22 KR KR10-2004-7017684A patent/KR20040106455A/ko not_active Ceased
- 2003-04-22 AU AU2003222395A patent/AU2003222395A1/en not_active Abandoned
- 2003-04-22 HR HRP20041029 patent/HRP20041029A2/xx not_active Application Discontinuation
- 2003-04-22 WO PCT/IB2003/001684 patent/WO2003093499A2/en not_active Ceased
- 2003-04-22 BR BRPI0309746-3A patent/BR0309746A/pt not_active IP Right Cessation
- 2003-04-22 CN CNA038095335A patent/CN1668761A/zh active Pending
- 2003-04-22 CA CA002484600A patent/CA2484600A1/en not_active Abandoned
- 2003-04-22 RU RU2004132198/15A patent/RU2303259C2/ru not_active IP Right Cessation
- 2003-04-22 MX MXPA04010777A patent/MXPA04010777A/es unknown
- 2003-04-22 JP JP2004501635A patent/JP2005524402A/ja active Pending
- 2003-04-28 TW TW092109924A patent/TWI269812B/zh not_active IP Right Cessation
-
2004
- 2004-02-13 US US10/779,212 patent/US20040162294A1/en not_active Abandoned
- 2004-10-20 NO NO20044470A patent/NO20044470L/no not_active Application Discontinuation
- 2004-10-21 IL IL16477804A patent/IL164778A0/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005524402A5 (enExample) | ||
| RU2004132198A (ru) | Терапевтическое применение селективных ингибиторов pde10 | |
| WO2009127642A3 (en) | Use of lrrk2 inhibitors for neurodegenerative diseases | |
| WO2008033460A3 (en) | Treating pain, diabetes, and lipid metabolism disorders | |
| WO2004078144A3 (en) | Diphenylethylene compounds and uses thereof | |
| Li et al. | Partial depletion and repopulation of microglia have different effects in the acute MPTP mouse model of Parkinson’s disease | |
| WO2008002594A3 (en) | Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors | |
| MX2009013990A (es) | Metodos para tratar enfermedades y trastornos mediados por serotonina. | |
| WO2007133673A3 (en) | Methods of treating a neurological disorder with creatine monohydrate | |
| EA200971050A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений | |
| GEP20115172B (en) | Bicyclic cinnamide compound | |
| WO2009143178A3 (en) | Pde10 inhibitors and related compositions and methods | |
| WO2008064342A3 (en) | Pde10 inhibitors and related compositions and methods | |
| JP2019533642A5 (enExample) | ||
| Small | Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer’s disease: do we need new inhibitors? | |
| WO2008064136A3 (en) | Compounds with activity at retinoic acid receptors | |
| WO2017027136A2 (en) | Therapeutic agents containing cannabis flavonoid derivatives for the prevention and treatment of neurodegenerative disorders | |
| WO2008136863A3 (en) | Synthesis of compounds useful as modulators of amyloid-beta production | |
| WO2006026747A3 (en) | Diphenylethylene compounds and uses thereof | |
| Xu et al. | Design and synthesis of reboxetine analogs morpholine derivatives as selective norepinephrine reuptake inhibitors | |
| MA29496B1 (fr) | Procede de production de 4-biphenylyazetidin-2-ones | |
| Gil et al. | Increased sensitivity to nicotine-induced seizures in mice heterozygous for the L250T mutation in the α7 nicotinic acetylcholine receptor | |
| WO2005019474A3 (en) | Human autism susceptibility gene and uses thereof | |
| Kim et al. | Oxcarbazepine and its active metabolite,(S)‐licarbazepine, exacerbate seizures in a mouse model of genetic generalized epilepsy | |
| CA3233141A1 (en) | Alpha-hydroxylated fatty acids metabolites, medical uses of same and use as biomarkers |